<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>markedly decline based on DiO labeling. This suggests that techniquemodifications may be required to optimize intra-stromal stem cellviability. Antibody staining for markers of human stem celltransplantation and keratocyte differentiation may also aid ourunderstanding of corneal stem cell fate and verify loss of cells orlabeling.Commercial Relationships: Behdad Kavianpour, None; GeraintJ. Parfitt, None; Hongshan Liu, None; Winston W. Kao, None;Donald J. Brown, None; Yilu Xie, None; Mikhail Geyfman, None;James V. Jester, None; Jennifer Simpson, NoneSupport: NIH Grant EY022365 Mesenchymal Stem Cell TherapyFor <strong>Cornea</strong>l Cystinosis; Research to Prevent Blindness, Inc;Discovery Eye Foundation; The Skirball Program in MolecularOphthalmology; The Cystinosis Research FoundationProgram Number: 1013 Poster Board Number: B0318Presentation Time: 1:00 PM - 2:45 PMInfluence of Secreted Ly6/uPAR-Related Protein-1 (Slurp1) on<strong>Cornea</strong>l Stromal Fibroblast Proliferation, Interaction with theExtracellular Matrix, and MigrationShivalingappa K. Swamynathan 1, 2 , Sudha Swamynathan 1 .1 Ophthalmology, Univ Pittsburgh Sch of Med, Pittsburgh, PA; 2 CellBiology and Physiology, Univ Pittsburgh Sch of Med, Pittsburgh,PA.Purpose: Previously, we demonstrated that the secreted Ly6/uPARrelatedprotein-1 (Slurp1) is abundantly expressed in the cornea andis downregulated in diverse pro-inflammatory conditions. Here, weexamine the effects of Slurp1 on corneal stromal fibroblast cellproliferation, interaction with the extracellular matrix (ECM), andmigration, to understand the cellular basis of Slurp1 functions in thecornea.Methods: The effect of Slurp1 on corneal fibroblast behavior wasassessed in vitro by treating human telomerase reverse transcriptase(hTERT)-immortalized mouse corneal stromal cell line MK/T1 withhistidine-tagged mouse Slurp1 (His-Slurp1) produced in E. coli andpartially purified by Ni ion resin column chromatography. Effect ofHis-Slurp1 on MK/T1 cell (i) density was assessed by crystal violetstaining followed by measurement of absorbance at 590 nm, (ii)interaction with the ECM was evaluated on cell culture plates coatedwith different ECM components, and (iii) migration was assessed byin vitro gap filling assays.Results: Compared with the control, His-Slurp1-treated mousecorneal stromal fibroblast MK/T1 cells (i) density increased at aslower pace suggesting that Slurp1 inhibits cell proliferation, (ii)adhered with lower affinity to collagen-I-, collagen-IV-, vitronectinorfibronectin-coated culture plates suggesting that Slurp1 affectscell-matrix interaction, and (iii) migrated at a slower pace in gapfilling assays suggesting that Slurp1 inhibits cell migration.Conclusions: Our results demonstrate that Slurp1 inhibits cornealstromal fibroblast MK/T1 cell proliferation, cell-matrix adhesion andmigration, revealing the cellular basis for corneal functions of Slurp1.These results are consistent with the decreased expression of Slurp1in corneas exposed to pro-inflammatory conditions where the stromalfibroblasts proliferate at a higher rate, and migrate rapidly.Commercial Relationships: Shivalingappa K. Swamynathan,None; Sudha Swamynathan, NoneSupport: Department of Ophthalmology, University of PittsburghStart-up funds, Eye and Ear Foundation of Pittsburgh, Research toPrevent Blindness and NIH core grant P30 EY08098Program Number: 1014 Poster Board Number: B0319Presentation Time: 1:00 PM - 2:45 PMStromal Cells derived from Amniotic Membrane are capable toreestablish corneal opacityYonathan Garfias 1, 2 , Alejandro Navas 1 , Jessica Nieves-Hernández 1 ,Gibran A. Estua 1 , Rodrigo Bolaños-Jiménez 1 . 1 Research Unit,Institute of Ophthalmology, Mexico City, Mexico; 2 Biochemistry,Faculty of Medicine, Universidad Nacional Autónoma de México,Mexico City, Mexico.Purpose: Stromal mesenchymal stem cells are non-hematopoieticderived cells found in the bone marrow stroma such as in manystromal tissues. The amniotic membrane is an elastin and avascularfetal membrane that is in contact to the fetus. A mature amnioticmembrane possesses 20-50 x 10 mesenchymal cells. .By the other hand, there are many corneal disorders that directlyaffect the corneal limbus, driving inflammation, conjunctivalizationor neovascularization of the corneal tissue. The pronostic depends onthe injured area of the limbus where the corneal stem cells arelocalized. Although, it has recently reported that the cells derivedfrom the amniotic membrane mesenchyma are source toadipogenesis, chondrogenesis, osteogenesis and myogenesis, itsfunction as a source for regeneration of the ocular surface has notbeen studied.The aim of the present study is to determine the utility of these cellsto restablish the ocular surface in a chemical burn murine model.Methods: Mesenchymal cells were obtained from a placenta usingdispase/collagenase method. The cells were cultured andcharacterized by flow cytometry. Cellular transdifferentiation assayswere performed using conditioned media. A murine chemical burnwas performed in order to determine the efficacy of these cells torestablish the corneal clarity. <strong>Cornea</strong>l histology was performed toidentify the incorporation of human mesenchymal cells in the murinecornea.Results: The cells obtained from the amniotic membranemesenchyma were capable to attach to the plastic wells showing afibroblast-like morphology. These cells presented mesenchymal stemcell markers such as CD29, CD73, CD44 and CD105, meanwhile,they were negative to CD45 and HLA-DR. Interestingly, these cellswere capable to differentiate into neurons and chondrocytes. Whenthese cells were intracamerally injected in a mouse burn model, thecorneal opacity was significantly reduced in comparison to theuntreated cornea. When the histology of the cornea was performed, itwas evident that the human amniotic membrane cells wereincorporated to the mouse cornea, reestablishing the structure of thecorneal tissue.Conclusions: The use of cells derived from the mesenchyma of theamniotic membrane is an important cell source to be used in theregenerative ophthalmology.Commercial Relationships: Yonathan Garfias, Institute ofOphthalmology (P); Alejandro Navas, None; Jessica Nieves-Hernández, Institute of Ophthalmology (P); Gibran A. Estua,None; Rodrigo Bolaños-Jiménez, NoneSupport: CONACYT 160286Program Number: 1015 Poster Board Number: B0320Presentation Time: 1:00 PM - 2:45 PM<strong>Cornea</strong>l endothelial cells derived from monkey iPS cells: a shortterm evaluationShin Hatou 1 , Satoru Yoshida 1 , Kazunari Higa 2 , Hideyuki Miyashita 1 ,Emi Inagaki 1 , Erika Kimura 3 , Ryuhei Hayashi 3 , Kazuo Tsubota 1 ,Kohji Nishida 3 , Shigeto Shimmura 1 . 1 Department of Ophthalmology,Keio Univ School of Medicine, Shinjuku-ku, Japan; 2 Department ofOphthalmology, Tokyo Dental College Ichikawa General Hospital,Ichikawa, Japan; 3 Department of Ophthalmology, Osaka University,Osaka, Japan.©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>Purpose: To evaluate the short term function of tissue-engineeredcorneal endothelial cells (TECE cells) derived from monkey inducedpluripotent stem cells (iPS cells).Methods: Cynomolgus monkey iPS cells were cultured in KSRmedium for 1 week and subsequently in N2 medium for 1 week,supplemented with TGF-beta inhibitor and BMP inhibitor. The iPSderivedneural crest cells were isolated as CD271 positive fraction bycell sorter. Next these cells were proliferated with EGF and FGF2,and subsequently medium was changed to an “endothelium-derivingmedium” including GSK-3beta inhibitor, retinoic acid and ROCKinhibitor. These cells were dispersed on collagen sheet and TECE cellsheets were obtained. The pump function attributable to Na,K-ATPase activity of TECE cell sheets was measured with an Ussingchamber, and compared with that of human corneal endothelial cellline (B4G12 cells). In vivo function of TECE was measured ascentral corneal thickness of rabbit eyes transplanted with TECE cellsheets for 8 days after surgery and compared with control eyesdeprived of endothelium.Results: Hexagonal mosaic pattern monolayer TECE cells wereobtained. Pump function of TECE was 2.34±0.46 mV, whereas thatof B4G12 cells was 1.07±0.20 mV. The corneal thickness of TECEtransplanted rabbit eyes (589.25±164.8μm) maintained significantlower corneal thickness than control eyes (1105.8±165.9μm)throughout the post-operative period.Conclusions: In vitro and short term in vivo function of monkey iPSderivedTECE were observed. Further long-term in vivo evaluation ofTECE transplantation to monkey eyes is needed.Commercial Relationships: Shin Hatou, None; Satoru Yoshida,None; Kazunari Higa, None; Hideyuki Miyashita, None; EmiInagaki, None; Erika Kimura, None; Ryuhei Hayashi, None;Kazuo Tsubota, AcuFocus, Inc (C), Allergan (F), Bausch LombSurgical (C), Functional visual acuity meter (P), JiNS (P), Kissei (F),Kowa (F), Santen, Inc. (F), Otsuka (F), Pfizer (C), Thea (C), EchoDenki (P), Nidek (F), Ophtecs (F), Wakasa Seikatsu (F), CEPTCompany (P); Kohji Nishida, Alcon (C), Alcon (F), HOYA (F),Senju (F), Pfizer (F), Santen (F), Osaka University (P); ShigetoShimmura, NoneSupport: Highway Program for realization of regenerative medicinefrom Ministry of Education, Culture, Sports, Science andTechnology, Japan.Program Number: 1016 Poster Board Number: B0321Presentation Time: 1:00 PM - 2:45 PMBone Marrow-Derived Endothelial Progenitor Cells forTreatment of <strong>Cornea</strong>l Endothelial DysfunctionYao Fu, Chunyi Shao, Xianqun Fan. Department of Ophthalmology,Ninth People’s Hospital, Medical School of Shanghai JiaotongUniversity, Shanghai, China.Purpose: To investigate the feasibility of inducing bone marrowderivedendothelial progenitor cells (BEPC) to differentiate intocorneal endothelial cells (CEC) for the treatment of cornealendothelial dysfunction.Methods: BEPC were isolated from human fetal bone marrow, andexpression of Dil-Ac-LDL, UEA-1, CD133 and CD34 wereexamined to identify the cells. BEPC were co-cultured with CEC for10 days in a transwell system with conditioned medium from CEC,and then cell transdifferentiation was examined byimmunocytofluorescence and electron microscopy. With a porcinecorneal acellular matrix as the carrier, the induced BEPC weretransplanted onto a cat’s cornea from which Descemet’s membraneand the endothelium had been stripped.Results: The induced BEPC resembled CEC in polygonal shape,expressing aquaporin-1, tightly opposed cell junctions, and neuronespecificenolase. Twenty-eight days after transplantation, thetransparency gradually returned to the corneas transplanted with theinduced BEPC on porcine corneal acellular matrix .Conclusions: Human fetal BEPC could be induced into cornealendothelial-like cells in vitro. Features of the induced BEPCindicated that they may be useful for the treatment of cornealendothelial dysfunction.Commercial Relationships: Yao Fu, None; Chunyi Shao, None;Xianqun Fan, NoneSupport: grant from the National Nature Science Foundation ofChina (81000366)Program Number: 1017 Poster Board Number: B0322Presentation Time: 1:00 PM - 2:45 PMStandardization of human corneal endothelial cell isolation andthe use of denuded amniotic membrane as a scaffold for humancorneal endothelial cellsKalpana Suresh, Tanvi Khanna, Alan M. Punnoose, Sarah Kuruvilla,Vishnu D. Narayanam, RAMYA RAVINDRAN, Varshini Varadaraj.Ophthalmology, Sri Ramachandra Universiy, Chennai, India.Purpose: To identify the best technique for complete denudation ofamniotic membrane.To standardize the isolation of human corneal endothelial cells.To use the denuded amniotic membrane as a scaffold for isolatedhuman corneal endothelial cells.Methods: Human amniotic membrane denudation was carried outusing 1.2 units/ml of Dispase II at 37degree C for 60 minutesfollowed by mechanical scraping and microscopic examination. Thiswas followed by isolation of corneal endothelial cells using humandonor cadaveric eyes unfit for surgical usage. <strong>Cornea</strong>l endothelial anddescemet’s membrane sheets were peeled in a manner similar tocapsulorrhexis after corneoscleral button excision and enzymaticallydigested with 2mg/ml of collagenase II solution at 37 degree C and 5% CO2 for 2 hrs. Pre plating was done onto an uncoated culture wareto separate any attached fibroblasts from the endothelial cells whichwere then seeded onto denuded amniotic membrane in OptiMEMmedia supplemented with human epidermal growth factor, fibroblastgrowth nerve growth factor and bovine pituitary extract. The cellswere analyzed microscopically to assess if they maintained theirpolygonal morphology and subjected to RT-PCR analysis for Keratin3, neuron specific enolase, Vimentin and collagen VIII mRNAmarkers.Results: Microscopic examination of the denuded amnioticmembrane showed no epithelial cell remnants and an underlyingexposed stromal collagen. Peeling of the corneal endothelial anddescemet’s membrane gave sheets of ideal thickness exhibitingtypical cobblestone morphology. Enzymatic digestion of theharvested corneal tissue left behind acellular descemet’s sheets withthe endothelial cells seen floating individually or in tightly packedclusters with preplating aiding in a more fibroblast free endothelialcell isolation. Microscopic evaluation showed that a few isolated cellsmanaged to scaffold onto the amniotic membrane and that theymanage to retain that adhesion during subsequent mediareplacements.Conclusions: Usage of Dispase-II for enzymatic digestion ofamniotic membrane yielded a complete denudation which acted as asuccessful scaffold for harvested corneal endothelial cells. Furtherstudies can be done for endothelial cell proliferation serving as an invitro model for corneal tissue engineering studies.Commercial Relationships: Kalpana Suresh, None; TanviKhanna, None; Alan M. Punnoose, None; Sarah Kuruvilla, None;Vishnu D. Narayanam, None; RAMYA RAVINDRAN, None;Varshini Varadaraj, None©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33: ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35: ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37: ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39: ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41: ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43: ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45: ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47: ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49: ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51: ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53: ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55: ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57: ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59: ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61: ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63: ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65: ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67: ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69: ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71: ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73: ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75: ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77: ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79: ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81: ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85: ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87: ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89: ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91: ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93: ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95: ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97: ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99: ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101: ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103: ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105: ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107: ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109: ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111: ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113: ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115: ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117: ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119: ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121: ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123: ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125: ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127: ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129: ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131: ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133:
ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135:
ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137:
ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139:
ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141:
ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143:
ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145:
ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147:
ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149:
ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151:
ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153:
ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155:
ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157:
ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159:
ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161:
ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163:
ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165:
ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167:
ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169:
ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171:
ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173:
ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175:
ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177:
ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179:
ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181:
ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183:
ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185:
ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187:
ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189:
ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191:
ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193:
ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195:
ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197:
ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199:
ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201:
ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203:
ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205:
ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207:
ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209:
ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211:
ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213:
ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215:
ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217:
ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219:
ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221:
ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223:
ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225:
ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227:
ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229:
ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231:
ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233:
ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235:
ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237:
ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239:
ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241:
ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243:
ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245:
ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247:
ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249:
ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251:
ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253:
ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255:
ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257:
ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259:
ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261:
ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263:
ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265:
ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267:
ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269:
ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271:
ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273:
ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275:
ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277:
ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279:
ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281:
ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283:
ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285:
ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287:
ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289:
ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291:
ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293:
ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295:
ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297:
ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299:
ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301:
ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303:
ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305:
ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts